Antipsychotics do help many with schizophrenia, study finds

May 3, 2012
Antipsychotics do help many with schizophrenia, study finds
More than 50 years of data shows the drugs cut relapse rates, although side effects common.

(HealthDay) -- A new study finds that antipsychotic drugs can help many people with schizophrenia, cutting patients' risk of relapse by 60 percent.

The study, involving data stretching back 50 years, also found that who take antipsychotics are much less likely to be hospitalized and may behave less aggressively and have a better quality of life than patients who don't take the drugs.

One expert said the finding mirrors what he and other professionals have experienced.

The data "is consistent with what we see in clinical practice -- that we are very well able to keep our patients functioning better and out of the hospital when they consistently take these medications," said Dr. Roberto Estrada, attending psychiatrist at Lenox Hill Hospital in New York City.

The findings are published in the May 3 online edition of The Lancet.

In the study, German researchers combed through findings from 65 reported in 116 articles published between 1959 and 2011. The trials included nearly 6,500 patients with schizophrenia.

After one year, were 27 percent among patients who took antipsychotic drugs and 64 percent among those who took an inactive , the review found. Rates of hospital readmission were 10 percent for patients who took antipsychotics and 26 percent for those who took a placebo.

Evidence from five studies indicated that patients who took antipsychotic drugs behaved less aggressively, and findings from three studies suggested that they have a better quality of life.

Antipsychotic drugs are the main type of treatment for people with schizophrenia, but they can cause serious side effects. Indeed, the investigators found that patients who took antipsychotic drugs had more negative side effects than those who took a placebo, including movement disorders (16 percent versus 9 percent), sedation (13 percent versus 9 percent), and (10 percent versus 6 percent).

Antipsychotic medications can also be expensive, the authors noted. In 2010, about $18.5 billion was spent worldwide on antipsychotic drugs, according to a journal news release.

Estrada agreed that the drugs have their drawbacks. "The cost and adverse effects associated with antipsychotics remain major impediments to achieving more successful treatment of schizophrenia," he said. "Further work needs to be done to develop more effective treatments for schizophrenia that are better-tolerated and thus likely to improve patients' adherence to taking these medications."

Still, the take-home message from the new study is clear, the study authors said.

"Antipsychotic maintenance treatment substantially reduces relapse risk in all patients with schizophrenia for up to 2 years of follow-up," Stefan Leucht from the Technical University of Munich, and colleagues, said in a journal news release "The effect was robust in important subgroups such as patients who had only one episode, those in remission," he added.

Benefits seemed to occur regardless of whether patients took older or newer forms of antipsychotic drugs, Leucht added. However, for many patients "the drugs seemed to lose their effectiveness with time," he said.

Another expert said that, while the medications are not perfect, they have eased the suffering of many patients.

"This study confirms clinical observations going back to the early 1950s -- that is, are effective in reducing the symptoms associated with . The decreased number of patients in long-term mental health facilities, such as state mental hospitals, is a testimonial to this," said Dr. Norman Sussman, a psychiatrist at NYU Langone Medical Center and professor at the NYU School of Medicine in New York City.
"Hopefully, even better treatments will emerge in the near future that have fewer adverse effects and more robust therapeutic impact on cognition and social functioning," Sussman said.

Explore further: Atypical antipsychotics may aid symptons for some off-label uses, but not others

More information: The U.S. National Institute of Mental Health has more about schizophrenia.

Related Stories

Atypical antipsychotics may aid symptons for some off-label uses, but not others

September 27, 2011
Medical evidence suggests that psychiatric drugs known as atypical antipsychotics are effective in reducing symptoms for some off-label conditions, but not others, according to a new RAND Corporation study.

Antipsychotic drug combinations are often given to patients early in treatment

March 16, 2012
Patients with schizophrenia and other mental illnesses are commonly prescribed high dose combinations of antipsychotic drugs earlier than recommended by some guidelines, finds a new study in the March issue of General Hospital ...

Recommended for you

Probing how Americans think about mental life

October 20, 2017
When Stanford researchers asked people to think about the sensations and emotions of inanimate or non-human entities, they got a glimpse into how those people think about mental life.

Itsy bitsy spider: Fear of spiders and snakes is deeply embedded in us

October 19, 2017
Snakes and spiders evoke fear and disgust in many people, even in developed countries where hardly anybody comes into contact with them. Until now, there has been debate about whether this aversion is innate or learnt. Scientists ...

Inflamed support cells appear to contribute to some kinds of autism

October 18, 2017
Modeling the interplay between neurons and astrocytes derived from children with Autism Spectrum Disorder (ASD), researchers at University of California San Diego School of Medicine, with colleagues in Brazil, say innate ...

Study suggests psychedelic drugs could reduce criminal behavior

October 18, 2017
Classic psychedelics such as psilocybin (often called magic mushrooms), LSD and mescaline (found in peyote) are associated with a decreased likelihood of antisocial criminal behavior, according to new research from investigators ...

Taking probiotics may reduce postnatal depression

October 18, 2017
Researchers from the University of Auckland and Otago have found evidence that a probiotic given in pregnancy can help prevent or treat symptoms of postnatal depression and anxiety.

Schizophrenia disrupts the brain's entire communication system, researchers say

October 17, 2017
Some 40 years since CT scans first revealed abnormalities in the brains of schizophrenia patients, international scientists say the disorder is a systemic disruption to the brain's entire communication system.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.